Effect of ashwagandha (<i>Withania somnifera</i>) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study
Rai HP, Mishra DN
Journal of psychopharmacology (Oxford, England) · 4 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2025-03-18 · J Psychopharmacol · vol. 39 · issue 4 · pp. 350–363
- Publisher
- SAGE Publishing
- Cited
- 8 citations · more than 98% of similar papers · 9.0× the field average
- Impact
- Top 10% most cited in its field
- References
- 69 works
- Access
- Paywalled
- Research areas
- Phytochemicals and Medicinal Plants · Medicinal Plants and Neuroprotection · Pharmacology and Nanomedicine Research
- Keywords
- Wechsler Memory Scale, Placebo, Montreal Cognitive Assessment, Cognition, Randomized controlled trial, Wechsler Adult Intelligence Scale, Psychology, Audiology, Verbal memory, Working memory, Memory span, Placebo-controlled study, Medicine, Physical therapy, Cognitive impairment, Psychiatry, Double blind, Internal medicine
- MeSH
- humans, withania, plant extracts, treatment outcome, pilot projects, double-blind method, cognition, memory, neuropsychological tests, adult, aged, middle aged, female, male, cognitive dysfunction
2 authors
From IN
- Hari Prakash · corresponding
- Deo Nidhi MishraNirma (India)
Abstract
Background
Mild cognitive impairment (MCI) is a condition in which people have memory or thinking problems than other people of their age. This study evaluated the effectiveness and safety of ashwagandha extract standardized with Sominone (Somin-On™) in enhancing memory and cognitive functioning in adults with MCI.
Methods
In this randomized double-blind, placebo-controlled pilot study, 40 subjects with MCI were randomized in a 1:1 ratio to receive either Somin-On™ (250 mg daily) or a placebo for 60 days. The outcome measures, improvement in memory and other cognitive functions after 30 and 60 days were assessed using Montreal Cognitive Assessment (MoCA); Mini-mental state examination (MMSE); Wechsler Memory Scale-III (WMS-III)); and Shepard mental rotation task.
Results
Subjects treated with Somin-On™ showed significant improvements in immediate memory, general memory, working memory and visuospatial processing and the response assessed using WMS-III after 30 and 60 days outperforming the placebo group. Scores on the Shepard Mental Rotation test in Somin-On™ group showed a significant rise by 12.22% at 30 days and 31.67% at 60 days, from baseline. Significant improvement was observed with Somin-On™ in memory assessment scales viz. MoCA (7.83% at 30 days and 14.77% at 60 days, from baseline) and MMSE (9.26% at 30 days and 19.21% at 60 days, from baseline) compared to placebo group.
Conclusions
The supplementation of Somin-On™ is an effective therapy to improve the immediate, general and working memory, as well as cognitive functions like attention and information processing speed in adults with MCI.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.